BLASUBCUTANEOUSINJECTABLE
Approved
Feb 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) by Roche is her2/neu/cerbb2 antagonists [moa]. Approved for endoglycosidase [epc]. First approved in 2019.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HERCEPTIN HYLECTA is a subcutaneous formulation combining trastuzumab (a HER2-directed monoclonal antibody) with hyaluronidase enzyme to enable faster, less-volume subcutaneous delivery. It is indicated for HER2-positive breast cancer and works by antagonizing HER2/Neu/cerbB2, blocking growth signaling in HER2-overexpressing tumors.
$0.514MPart D
PeakAt peak lifecycle stage with modest Part D spending (~$514K in 2023), indicating established market penetration but limited near-term growth trajectory; commercial team likely focused on market maintenance and competitive defense.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
Endoglycosidase
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Phase 1 Comparative Study to Evaluate Pharmacokinetics, Immunogenicity, Safety and Tolerability of Bmab3000 and Herceptin Hylecta® After a Single 600 mg SC Injection in Healthy Male Volunteers
Started Feb 2026
150 enrolled
Healthy Male Participants
Career Relevance
HERCEPTIN HYLECTA offers stable career opportunities in a mature, peak-stage asset within Roche's oncology portfolio; roles focus on market defense, payer negotiation, and patient convenience optimization rather than novel indication expansion. Working on this product provides solid experience in established biologic management but limited exposure to early-stage innovation or growth-phase urgency.
Brand Manager
Worked on HERCEPTIN HYLECTA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.